Top Story Today
Lilly Just Made the Obesity Pill That Could End the Needle Era
The FDA approved Foundayo, Eli Lilly's once-daily oral obesity pill, and it changes the entire GLP-1 game. At $25/month with commercial insurance, it undercuts Novo Nordisk's oral Wegovy on both price and convenience: no fasting, no food restrictions, take it whenever you want. Weight loss averaged 12.4% at the highest dose over 72 weeks (less than injectables, but most patients will happily trade peak efficacy for skipping the needle). Lilly stockpiled $1.5 billion in inventory to avoid the shortages that plagued earlier launches, and the pill's small-molecule chemistry makes it far easier to mass-produce than Novo's peptide-based rival.
Why it matters: With the anti-obesity market projected to hit $100 billion by 2033, a convenient, affordable pill opens the floodgates for millions of patients who would never have picked up a syringe. This is the moment GLP-1 therapy goes truly mainstream.
Read more →Trade & Policy
100% Tariffs on Drug Imports: The White House's Biggest Stick Yet
The Trump administration issued a presidential proclamation slapping 100% tariffs on patented pharmaceutical imports, the most aggressive pharma trade action in modern U.S. history. Companies can drop the rate to 20% by committing to build factories stateside, or to 0% by matching international drug prices. Pfizer already pledged $70 billion in domestic production.
Read more →The UK Dodged America's Pharma Tariff Wall. The Price Wasn't Cheap.
Britain secured the only 0% tariff deal on pharmaceutical exports to the U.S., good through January 2029. The trade-off: NHS net prices for new medicines jump 25%, and the UK committed to raising total drug spending from 0.3% to 0.6% of GDP by 2035. AstraZeneca and GSK had already negotiated individual protections. Every other major exporting country is watching nervously.
Read more →Clinical & Regulatory
A Gene Editor That Doesn't Cut DNA Just Landed in the NEJM
Beam Therapeutics published peer-reviewed data in the New England Journal of Medicine showing its base-editing sickle cell therapy eliminated severe pain crises in all 31 patients treated. Fetal hemoglobin levels topped 60%, matching asymptomatic carriers. Unlike CRISPR, base editing rewrites DNA letters without breaking the strand, a precision advantage that could reshape the gene therapy landscape.
Read more →Spinraza Gets a Second Life With a Higher Dose
The FDA approved Biogen's high-dose Spinraza for spinal muscular atrophy, clearing a path back into a market where it was losing ground to Zolgensma and Evrysdi. Infants on the higher regimen gained 15.1 points on a motor function scale while controls worsened by 11.1 points. The broad label covers all SMA patients, and the approval validates dose optimization as a competitive strategy for aging genetic medicines.
Read more →Deals & Funding
A Peptide Startup Raised $250M in Six Months With Zero Clinical Data
Beijing-based Syneron Bio closed a $150 million Series B, just three months after a $100 million Series A. The company's AI-powered platform designs macrocyclic peptides that can hit "undruggable" protein targets. AstraZeneca and Abu Dhabi's sovereign wealth fund invested. Syneron also has a collaboration deal with AstraZeneca worth up to $3.4 billion in development and commercial milestones, though no drugs have entered human testing yet.
Read more →Ferring Pulls the Plug on Fertility Drug Trials
Ferring Pharmaceuticals halted its fertility drug clinical trials after a strategic portfolio review, part of a broader trend of mid-size pharma companies pruning pipelines amid rising cost pressures. The move leaves the reproductive health space with even fewer active developers, a concern for a therapeutic area that already struggles to attract large-company investment.
FierceBiotech →